Competition is intensifying in the self-driving AI sphere. At the highly influential Consumer Electronics Show (CES) in Las Vegas, one company unveiled a suite
Michael Burry Says He Isn’t Shorting Tesla Stock. What Does That Mean for You in 2026?
Tesla (TSLA) is facing a tough week, as its claim to be the global leader in electric vehicle (EV) sales no longer holds water.
Wall Street Extends Rally with Amazon, Nvidia, Restaurant Stocks Jumping | The Financial Market
Stocks are continuing to rally on Tuesday afternoon. Nvidia is jumping after CEO Jensen Huang outlined the next phase of AI at CES, while
A Look At Nvidia (NVDA) Valuation As Growth Narratives Clash On Fair Value Estimates
NVIDIA (NVDA) continues to draw attention from investors, with the stock recently closing at $188.12. Short term returns are mixed, with a 1 day
AI boom warning sign? Nvidia's new chips hit data center cooling stocks
In a possible red flag for the artificial intelligence investment boom, the stocks of companies that provide cooling systems for data centers, plunged Tuesday
Data-Center Cooling Stocks Sink After Nvidia CEO’s CES Talk
(Bloomberg) — Makers of cooling systems saw their stocks sell off Tuesday after comments by Nvidia Corp.’s chief executive raised fears about demand for
The Best Growth ETFs to Invest $1,000 in Right Now
Geoffrey Seiler, The Motley Fool January 6, 2026 at 6:52 PM Key Points The Vanguard Growth ETF and Invesco QQQ Trust are great growth
Forget COLA: This Is the Social Security Number Retirees Need to Know In 2026
© Lane V. Erickson / Shutterstock.com For much of the year, more Social Security beneficiaries focus on the cost-of-living adjustment (COLA). The COLA directly
Buffett vs real estate: The 5-second stock deal that explains why he still bets on equities
Warren Buffett says stocks beat real estate on speed, liquidity and efficiency, arguing complex property deals rarely match the value of equities. Buffett says
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib
Investors today are cheering envudeucitinib’s Phase 3 edge in oral TYK2 psoriasis as well as Alumis’ plans to raise fresh capital. Today’s Change (95.31%)